Journal · Updated 2026-08-11
Michigan Medicaid and GLP-1s in 2026: The January 1 Restriction, the Morbid-Obesity Standard, and Every Door Still Open
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
Michigan still covers GLP-1 medications for weight loss under Medicaid — it appears on both KFF's January 2026 list of thirteen covering states and the July 2026 tracker counts of roughly eleven — but effective January 1, 2026, it does so under the strictest criteria of any covering state. Per MDHHS provider notification L 25-73, issued to implement the state's fiscal-year 2026 budget legislation, coverage of Wegovy, Zepbound, Saxenda, and generic liraglutide when prescribed solely for obesity now requires that the patient be classified as morbidly obese, have documented failure of all other clinically appropriate weight-loss interventions, have trialed and failed the preferred anti-obesity agents on the state's drug list, and be using the medication specifically to avert bariatric surgery. The restriction applies to every Michigan Medicaid member — fee-for-service and all managed-care plans alike. What did not change: coverage of GLP-1s for type 2 diabetes (Ozempic, Mounjaro), and the non-weight indication doors that federal rules keep open everywhere.
What January 1 actually changed, per the state's own paper
The FY2026 Michigan budget, passed in fall 2025, directed the state's Medicaid program to reduce GLP-1 weight-loss spending, and MDHHS implemented it through notification L 25-73 with the new clinical criteria posted to the state's pharmacy portal. Managed-care plans issued matching bulletins — Priority Health's December 15 notice and Meridian's December 16 bulletin both restate the same four-part test — and MDHHS and the plans mailed letters to members who had recently filled one of the affected drugs, starting in early December 2025. The four parts, together, not any one alone: morbid-obesity classification (trackers report the working threshold as a BMI of forty or higher), documented failure of all other clinically appropriate interventions, trial and failure of the preferred anti-obesity agents — phentermine and Qsymia remain covered as preferred options, each with its own prior authorization — and use of the GLP-1 as a measure to avert bariatric surgery. Prior authorization is required across the board, including for the non-weight indications.
The detail that catches existing patients
University of Michigan clinicians analyzing the policy flagged the transition mechanics: members who entered 2026 already on a previously authorized GLP-1 for weight management — a substantial majority of the state's users — keep coverage only until their existing six-month authorization expires, after which the new criteria apply to any renewal. There is no grandfather clause. The same analysis put the policy's reach at up to a million Michiganders with obesity or overweight and the state's projected 2026 savings at roughly two hundred forty million dollars. If your authorization is mid-cycle, the renewal date on your approval letter is the date that matters; the prior-authorization guide's documentation checklist is what a renewal under the new test requires.
Every door still open in Michigan
The restriction is scoped to the weight-loss indication, which leaves the standing doors intact. The diabetes door: Ozempic and Mounjaro coverage for type 2 diabetes is explicitly unchanged. The indication doors: Michigan's own plan bulletins state that Wegovy and Zepbound criteria were updated to include the non-weight indications — cardiovascular risk reduction and severe obstructive sleep apnea among them — with prior authorization, and the University of Michigan analysis adds Wegovy for severe liver disease to the covered list; the indication-door playbook maps the documentation each one takes. The under-21 path: the federal EPSDT benefit's individualized medical-necessity review continues for members under twenty-one. And the cash reality for everyone the new test excludes: the compounded market's floor sits near one hundred dollars a month for semaglutide and under one hundred seventy for tirzepatide on current promotional cards — figures that carry this site's standing verification homework and the reminder that a verified program at a fair price beats an unverified one at any price. The Medicaid hub holds the national picture; the change ledger holds every dated move.
Questions people ask
Does Michigan Medicaid still cover Wegovy or Zepbound for weight loss in 2026?
Yes, but under the strictest test of any covering state as of January 1, 2026: morbid-obesity classification (reported threshold BMI ≥40), documented failure of all other clinically appropriate interventions, trial and failure of preferred agents (phentermine, Qsymia), and use to avert bariatric surgery — all four, with prior authorization, per MDHHS notification L 25-73.
I was already approved before 2026 — do I keep my coverage?
Only until your current six-month authorization expires. University of Michigan clinicians analyzing the policy note there is no grandfathering: renewals after January 1, 2026 are judged under the new criteria, so the renewal date on your approval letter is the operative date.
What about Ozempic or Mounjaro for diabetes?
Unchanged. Michigan's bulletins state explicitly that GLP-1 coverage for type 2 diabetes was not affected by the January 1 restriction. The cardiovascular, sleep-apnea, and liver-disease indication doors also remain, each with prior authorization — the playbook covers the documentation.
Where are the official criteria posted?
MDHHS notification L 25-73 and the clinical PA criteria on the state's Medicaid pharmacy portal (operated with Prime Therapeutics), under the anti-obesity agents class. Priority Health and Meridian both published member-facing bulletins in December 2025 restating the same test.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.